跳至主要内容
临床试验/jRCTs031220373
jRCTs031220373已完成不适用

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the effect of high-dose nicotinamide mononucleotide (NMN) on aging

未提供0 个研究点目标入组 62 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
62
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized Controlled Trial
干预模型
Parallel Assignment
主要目的
Prevention Purpose
盲法
Double Blind

入排标准

年龄范围
65age old over 至 No limit(—)
性别
All

入选标准

  • Aged 65 years old or older at the time of informed consent is taken
  • Male or female
  • Able to attend all scheduled visits
  • Able and willing to give written informed consent

排除标准

  • Taking health food
  • With severe hearing loss or wearing a hearing aid in daily life
  • Taking more than 1 hour daily exercise for more than 6 months
  • With a pacemaker
  • Taking medicine, including Chinese medicine
  • Having history of treatment for cancer, heart failure and myocardial infarction
  • With atrial fibrillation, arrhythmia, liver failure, renal failure, cerebrovascular disease, rheumatoid arthritis and other chronic diseases except diabetes, dyslipidemia and hypertension
  • Suspected of having viral hepatitis, HIV or syphilis
  • With drug allergy or with food allergy to health food related to this study
  • Participated in other clinical trials within 3 months
  • Judged as ineligible by clinical investigators

结局指标

主要结局

-

Change from baseline in hearing ability after 24 weeks of treatment

次要结局

  • Physical function(24 weeks)
  • Blood tests(24 weeks)
  • Biomarkers(24 weeks)
  • DNA methylation age(24 weeks)
  • Skin condition(24 weeks)
  • Exercise tolerance assessed by the 6 minute walk test(24 weeks)
  • Gut and oral microbiota(24 weeks)
  • Number of mitochondria(24 weeks)
  • Quality of Life(24 weeks)
  • Correlation between blood NAD level and these items

研究者

发起方
未提供

相似试验